JP5601685B2 - Ａｐｏ（ａ）遺伝子における多型はアセチルサリチル酸治療に対する応答性を予測する - Google Patents

Ａｐｏ（ａ）遺伝子における多型はアセチルサリチル酸治療に対する応答性を予測する Download PDF

Info

Publication number
JP5601685B2
JP5601685B2 JP2010507475A JP2010507475A JP5601685B2 JP 5601685 B2 JP5601685 B2 JP 5601685B2 JP 2010507475 A JP2010507475 A JP 2010507475A JP 2010507475 A JP2010507475 A JP 2010507475A JP 5601685 B2 JP5601685 B2 JP 5601685B2
Authority
JP
Japan
Prior art keywords
subject
allele
ncbi
polymorphism
chromosome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010507475A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010528262A (ja
JP2010528262A5 (enExample
Inventor
ポール リドカー，
ダニエル チャズマン，
ダフ シッフマン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of JP2010528262A publication Critical patent/JP2010528262A/ja
Publication of JP2010528262A5 publication Critical patent/JP2010528262A5/ja
Application granted granted Critical
Publication of JP5601685B2 publication Critical patent/JP5601685B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
JP2010507475A 2007-05-09 2008-05-09 Ａｐｏ（ａ）遺伝子における多型はアセチルサリチル酸治療に対する応答性を予測する Active JP5601685B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91685807P 2007-05-09 2007-05-09
US60/916,858 2007-05-09
PCT/US2008/005986 WO2008140776A1 (en) 2007-05-09 2008-05-09 Polymorphism in the apo (a) gene predict responsiveness to acetylsalicylic acid treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013240542A Division JP2014036674A (ja) 2007-05-09 2013-11-21 Ａｐｏ（ａ）遺伝子における多型はアセチルサリチル酸治療に対する応答性を予測する

Publications (3)

Publication Number Publication Date
JP2010528262A JP2010528262A (ja) 2010-08-19
JP2010528262A5 JP2010528262A5 (enExample) 2013-05-23
JP5601685B2 true JP5601685B2 (ja) 2014-10-08

Family

ID=40002550

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010507475A Active JP5601685B2 (ja) 2007-05-09 2008-05-09 Ａｐｏ（ａ）遺伝子における多型はアセチルサリチル酸治療に対する応答性を予測する
JP2013240542A Withdrawn JP2014036674A (ja) 2007-05-09 2013-11-21 Ａｐｏ（ａ）遺伝子における多型はアセチルサリチル酸治療に対する応答性を予測する

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013240542A Withdrawn JP2014036674A (ja) 2007-05-09 2013-11-21 Ａｐｏ（ａ）遺伝子における多型はアセチルサリチル酸治療に対する応答性を予測する

Country Status (7)

Country Link
US (6) US7943317B2 (enExample)
EP (1) EP2150627B1 (enExample)
JP (2) JP5601685B2 (enExample)
CN (1) CN101743325B (enExample)
BR (1) BRPI0811309B1 (enExample)
CA (1) CA2686874C (enExample)
WO (1) WO2008140776A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5601685B2 (ja) * 2007-05-09 2014-10-08 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド Ａｐｏ（ａ）遺伝子における多型はアセチルサリチル酸治療に対する応答性を予測する
WO2013080227A1 (en) * 2011-11-28 2013-06-06 Decode Genetics Ehf Genetic variants useful for risk assessment of arterial disease
US20150227678A1 (en) * 2014-02-09 2015-08-13 Lane Bernard SCHEIBER Method to represent the nucleotide elements of a dna sequence as numerical elements to include adenine being assigned the value one, guanine being assigned the value two, cytosine being assigned the value three, and thymine being assigned the value four

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1806867C3 (de) * 1968-11-04 1974-07-18 Byk-Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur Herstellung substituierter 4-Hydroxy pyrimidine
US6992171B2 (en) * 2000-06-22 2006-01-31 Takeda Pharmaceutical Company Limited Polypeptide and its DNA
EP2500440B1 (en) * 2002-12-20 2015-12-16 Celera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
CA2518956A1 (en) * 2003-03-10 2004-09-23 Applera Corporation Single nucleotide polymorphisms associated with stenosis, methods of detection and uses thereof
EP2386657B1 (en) 2003-11-26 2014-01-08 Celera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
US20050287558A1 (en) 2004-05-05 2005-12-29 Crooke Rosanne M SNPs of apolipoprotein B and modulation of their expression
CA2566257A1 (en) 2004-05-07 2005-11-24 Applera Corporation Genetic polymorphisms associated with vascular diseases, methods of detection and uses thereof
US7381536B2 (en) 2005-03-01 2008-06-03 Gurbel Paul A Assessment of cardiac health and thrombotic risk in a patient
ATE480229T1 (de) * 2005-05-24 2010-09-15 Flamel Tech Sa Orale pharmazeutische zusammensetzung zur behandlung einer cox-2-vermittelten erkrankung
US7972802B2 (en) 2005-10-31 2011-07-05 University Of Washington Lipoprotein-associated markers for cardiovascular disease
US20100120045A1 (en) * 2007-04-30 2010-05-13 Decode Genetics Ehf Genetic variants useful for risk assessments of coronary artery disease and myocardial infarction
JP5601685B2 (ja) 2007-05-09 2014-10-08 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド Ａｐｏ（ａ）遺伝子における多型はアセチルサリチル酸治療に対する応答性を予測する

Also Published As

Publication number Publication date
JP2010528262A (ja) 2010-08-19
EP2150627A4 (en) 2011-02-23
US20140024623A1 (en) 2014-01-23
US20090004187A1 (en) 2009-01-01
BRPI0811309A2 (pt) 2020-09-15
CN101743325B (zh) 2014-07-09
CA2686874C (en) 2021-10-19
WO2008140776A1 (en) 2008-11-20
US10550433B2 (en) 2020-02-04
US20200248262A1 (en) 2020-08-06
US11697850B2 (en) 2023-07-11
US20170335394A1 (en) 2017-11-23
US20150284799A1 (en) 2015-10-08
CN101743325A (zh) 2010-06-16
EP2150627A1 (en) 2010-02-10
US20110206667A1 (en) 2011-08-25
US7943317B2 (en) 2011-05-17
EP2150627B1 (en) 2013-09-11
BRPI0811309B1 (pt) 2022-03-03
JP2014036674A (ja) 2014-02-27
CA2686874A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
CA2882487C (en) Genetic polymorphisms associated with stroke, methods of detection and uses thereof
JP2017529830A (ja) Ｈｄｌ上昇剤又はｈｄｌ模倣剤を用いた治療に対する応答性を予測するための遺伝マーカー
US11697850B2 (en) Polymorphism in the Apo(a) gene predict responsiveness to acetylsalicylic acid treatment
Jaramillo et al. Polymorphisms of the NOS3 gene in Southern Chilean subjects with coronary artery disease and controls
EP1651774B1 (en) Use of polymorphisms in human oatp-c associated with an effect on statin pharmacokinetics in humans in statin therapy
JP2010528262A5 (enExample)
US20080233582A1 (en) Single nucleotide polymorphisms associated with susceptibility to cardiovascular disease
Jaramillo et al. − 786T> C polymorphism of the endothelial nitric oxide synthase gene in Chilean subjects with coronary artery disease and controls
Gigante et al. Variants in the coagulation factor 2 receptor (F2R) gene influence the risk of myocardial infarction in men through an interaction with interleukin 6 serum levels
Pérez-Hernández et al. Protective role of DDAH2 (rs805304) gene polymorphism in patients with myocardial infarction
US20060240421A1 (en) Genetic polymorphisms sensitively predicting adverse drug reactions (adr) and drug efficacy
Abessolo et al. Enzymatic and genetic polymorphisms of paraoxonase-1 in the Gabonese population: the relation to lipid parameters in patients with diabetes
US20090208967A1 (en) Genetic Polymorphisms As Predictive Diagnostics For Adverse Drug Reactions (ADR) And Drug Efficacy
US20030044810A1 (en) Methods, compositions, and kits relating to cardiovascular disease
WO2007014338A2 (en) Single nucleotide polymorphisms associated with susceptibility to cardiovascular disease
EP1983062A1 (en) Single nucleotide polymorphisms associated with susceptibiliy to cardiovascular disease
Pascua Carboxylesterase 1 Genetic Variability, Expression and Potential for Drug-drug Interactions
Bonnet et al. Santorini Biologie Prospective Conference 2002 “From Genetic Variations to Risk Prediction and Pharmacogenomics”

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110506

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110506

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20110506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130821

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140711

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140722

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140813

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140815

R150 Certificate of patent or registration of utility model

Ref document number: 5601685

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250